CHEK2 and lung cancer: High-throughput functional assays to classify the degree of CHEK2 abrogation are becoming available and may be able to define variant-specific risks more precisely.41, 43 Previous studies have shown that the CHEK2*I157T variant is associated with a reduced risk for lung cancer.44